Antitumor effect of the curaxin CBL0137 on the models of colon cancer

Curaxins represent low molecular weight carbazole derivatives, which simultaneously activate p53-dependent apoptosis and inhibit NF-kBdependent signal transduction pathways. Antitumor activity of curaxin CBL0137 was demonstrated in vivo on the model of solid transplantable mouse colon adenocarcinoma Akatol. Significant tumor growth inhibition caused by CBL0137 treatment was observed. On the 37th day after tumor transplantation for CBL0137 oral doses 5, 10, 15 and 20 mg/kg the tumor growth inhibition indexes were 53, 50, 56 and 74 %, respectively. CBL0137 treatment extended life span of mice in all study groups receiving this test article. Maximum lifespan increase (81,7 %) was observed in the group of mice treated with 20 mg/kg dose of CBL0137. The cytotoxicity of CBL0137 was assessed on human colon cancer cells in vitro. We demonstrated that CBL0137 inhibits the expression COX2, which in its turn is known to exhibit antiapoptotic, pro-angiogenic and pro- metastatic properties. Thus, we demonstrated antitumor effect of CBL0137 against colon cancer in vitro and in vivo.

1. Torre L. A., Bray F., Siegel R. L. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87–108.

2. Dey A., Tergaonkar V., Lane D. P. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008;7(12): 1031–40.

3. Guo C., Gasparian A. V., Zhuang Z. et al. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009;28(8):1151–61.

4. Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol 2009;5(10):1685–704.

5. Dermawan J. K., Gurova K., Pink J. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 2014;13(9):2203–14.

6. Gasparian A. V., Burkhart C. A., Purmal A. A. et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med 2011;3(95):95ra74.

7. Barone T. A., Burkhart C. A., Safina A. et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide- responsive and -resistant glioblastoma. Neuro Oncol 2016.

8. Герасимова Г. К., Маркова Н. П., Голубева И. С. и др. Противоопухолевая активность препарата Стелланин на перевиваемых опухолях мышей. Российский биотерапевтический журнал 2014;(1): 43–8. [Gerasimova G. K., Markova N. P., Golubeva I. S. et al. Antitumor activity of the drug Stellanin on transplantable mice tumors. Russiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2014;(1):43–48. (In Russ.)].

9. Eberhart C. E., Coffey R. J., Radhika A. et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107(4):1183–8.

10. Taketo M. M. COX-2 and colon cancer. Inflamm Res 1998;47(Suppl 2):S112–6.

11. Jones M. K., Wang H., Peskar B. M. et al. Inhibition of angiogenesis by nonsteroidal anti- inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5(12):1418–23.

12. Tsujii M., Kawano S., DuBois R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94(7):3336–40.

13. Tessner T. G., Muhale F., Riehl T. E. et al. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 2004;114(11):1676–85.

14. Pozzi A., Yan X., Macias-Perez I. et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 2004;279(28):29797– 804.

15. Plummer S. M., Holloway K. A., Manson M. M. et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF- kB activation via the NIK/IKK signalling complex. Oncogene 1999;18(44):6013–20.

16. Olfert E., Bhasin J., Latt R. et al. The CCAC guidelines on: choosing an appropriate endpoint in experiments using animals for research, teaching and testing were developed by the ad hoc subcommittee on endpoints of the CCAC Guidelines Committee: Ernest O. et al. 1998.

17. Livak K. J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 2001;25(4):402–8.

18. de Jonge H. J., Fehrmann R. S., de Bont E. S. et al. Evidence based selection of housekeeping genes. PLoS One 2007;2(9):e898.